• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioSig Appoints Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer

    5/28/25 1:46:57 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BSGM alert in real time by email

    Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "combined company"), which today acquired Streamex Exchange Corporation ("Streamex") as its wholly owned subsidiary, announced the appointment of Mitch Williams, CFA, as Chief Investment Officer, significantly bolstering the combined company's leadership team and advancing its mission to tokenize real world assets and bring commodity markets on-chain.

    Key Highlights of the Appointment:

    • Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex, will be appointed Chief Investment Officer of the combined company.
    • Mr. Williams brings over 20 years of experience in capital markets, having held senior executive roles at OppenheimerFunds, and Wafra Inc.
    • At Wafra Inc., Mr. Williams grew assets under by more than 3-fold and consistently delivered asymmetric returns with top-quartile performance over all rolling five-year periods.
    • At OppenheimerFunds, Mr. Williams was the top-ranked equity analyst and led the firm's flagship fund.
    • Mr. Williams will help lead Streamex in its strategic positioning within the US$142.851 trillion global commodity market, aiming to unlock new value by bringing commodities on-chain through secure and scalable real world asset tokenization solutions.

    As CIO, Mitch will lead the combined company's strategic vision and commodity tokenization initiatives, while overseeing key areas and reporting directly to Chief Executive Officer Henry McPhie.

    Mitch commented, "As an early investor in Streamex and later a Strategic Advisor I have been consistently impressed with Henry, Morgan, and the team and the innovative platform they've built.  As a believer in disruptive technology, I see RWA tokenization as an incredibly scalable technology.  For me it is a leap forward in finding real world applications for blockchain- a technology whose value has only begun to be realized.  As an investor, I see Streamex as one of the few pathways for investors interested in both a hedge against fiat currency regimes and recurring revenue model."

    "We are thrilled to welcome Mitch as our new Chief Investment Officer," said Henry McPhie, Chief Executive Officer of the combined company. "Mitch's exceptional record of delivering disciplined, high-return investment strategies over his career at large New York funds paired with his collaborative leadership style perfectly complements our culture and growth ambitions. I am confident that his vision will unlock new opportunities for our shareholders, and I couldn't be happier to have him join our leadership team."

    About Mitch Williams

    In his over two decades on Wall Street, Mitch has had a front row seat for disruptive technologies and market innovation.  From his early role during Web 1.0 at Credit Suisse on the Internet Financial Services team to high-profile positions at OppenheimerFund and Wafra Inc managing multi-billion dollar domestic and global teams and portfolios, Mitch has driven consistent value creation for both his clients and employers. 

    At Wafra, Mitch grew assets under management by more than 3-fold during his tenure, delivering asymmetric returns characterized by upside capture consistently above 100% and downside capture below 100%. Under his lead Wafra achieved top-quartile performance for every rolling five-year period his team managed the Global Equity strategy. At OppenheimerFunds, he was a top-ranked analyst and took a leading role in managing one of the firm's flagship funds.

    As Chief Investment Officer at Streamex, Mitch will apply his deep capital markets expertise and strategic vision to shape the firm's direction. Prior to this role, he served as a Strategic Advisor on Capital Markets to Streamex, working closely with Streamex founders Henry, Morgan, and Mathew August to develop and implement transformative business strategies.

    Outside of his professional commitments, Mitch is an active mentor and speaker. He volunteers with the Michael Price Student Investment Fund at NYU's Stern School of Business and has spoken on investing at numerous leading universities. He holds an MBA from NYU Stern, where he was awarded the Stern Fellowship, and a BA from the University of Florida.

    About Streamex Exchange Corporation

    Streamex is a real-world asset (RWA) tokenization company focused in the commodities space. With the goal to bring commodity markets on chain, Streamex has developed primary issuance and exchange infrastructure that will revolutionize commodity finance. Streamex is led by a group of highly successful and seasoned executives from financial, commodities and blockchain industries.

    Streamex believes the future of finance lies in tokenization, innovative investment strategies, and decentralized markets. By merging advanced financial technologies with blockchain transparency, Streamex has created infrastructure and solutions that enhance liquidity, accessibility, and efficiency. Streamex's goal is to bridge the gap between traditional finance and the digital economy, unlocking new opportunities for investors and institutions worldwide.

    Forward Looking statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.   Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control.   It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether  we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the transaction will be obtained and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise.  For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled "Risk Factors" in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law. 



    Todd Adler
    BioSig Technologies, Inc.
    Investor Relations
    12424 Wilshire Blvd Ste 745
    Los Angeles, CA 90025
    [email protected]
    203–409–5444, x104
    
    Henry McPhie
    Co-Founder & CEO of Streamex, CEO of the Combined Company
    [email protected]
    https://www.streamex.com/
    https://x.com/streamex
    

    Primary Logo

    Get the next $BSGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BSGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Williams Mitchell Young claimed ownership of 1,000,000 units of Restricted Common Stock (SEC Form 3)

      3 - BioSig Technologies, Inc. (0001530766) (Issuer)

      6/9/25 6:31:07 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Mcphie Karl Henry Michael

      3 - BioSig Technologies, Inc. (0001530766) (Issuer)

      6/9/25 6:29:42 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Lekstrom Morgan Lee

      3 - BioSig Technologies, Inc. (0001530766) (Issuer)

      6/9/25 6:27:01 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    SEC Filings

    See more
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      7/9/25 9:22:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/30/25 4:05:38 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/27/25 6:02:01 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on BioSig Technologies with a new price target

      The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

      2/8/21 7:32:50 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1.1B USD in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets

      BioSig Technologies, Inc. (NASDAQ:BSGM), which recently merged with Streamex Exchange Corporation ("Streamex") to become one of largest public holders of gold bullion. Streamex' proprietary real-world asset (the "RWA") platform will bring the approx. $142 trillion commodities market on the blockchain powered by Streamex & Solana. The transaction was led by: Cantor Fitzgerald & Co., Clear Street LLC and Needham & Company, LLC acting as placement agents; and CIBC World Markets acting as Strategic Advisor to the BSGM board of directors and management. BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (

      7/7/25 6:41:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

      Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

      6/9/25 10:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

      Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Sean Roosen as Strategic Advisor to Streamex. Mr. Roosen, a globally recognized mining entrepreneur and financier, brings over three decades of experience in building and scaling multibillion-dollar resource ventures. Mr. Roosen is the Founder, Executive Chairman, and Chief Executive Officer of Osisko Development Corp., a premier North American gold development company. He is also the founder and former Executive Chairman and CE

      6/4/25 8:25:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Leadership Updates

    Live Leadership Updates

    See more
    • BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

      Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

      6/9/25 10:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

      Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Sean Roosen as Strategic Advisor to Streamex. Mr. Roosen, a globally recognized mining entrepreneur and financier, brings over three decades of experience in building and scaling multibillion-dollar resource ventures. Mr. Roosen is the Founder, Executive Chairman, and Chief Executive Officer of Osisko Development Corp., a premier North American gold development company. He is also the founder and former Executive Chairman and CE

      6/4/25 8:25:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CORRECTION: Streamex and BioSig Appoint Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer (CIO)

      Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies' leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex will be appointed Chief Investment Officer of the combined company. Mr, Williams, brings over 20 years of

      5/28/25 6:45:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Financials

    Live finance-specific insights

    See more
    • BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

      Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

      9/22/22 9:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig to Host Conference Call on December 21, 2021

      Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

      12/13/21 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      11/14/24 3:58:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioSig Technologies Inc.

      SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

      2/14/24 3:31:45 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      7/12/21 8:29:21 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care